Impact of infection on admission and of the process of care on mortality of patients admitted to the Intensive Care Unit: the INFAUCI study  by Gonçalves-Pereira, J. et al.
Impact of infection on admission and of the process of care on mortality
of patients admitted to the Intensive Care Unit: the INFAUCI study
J. Goncalves-Pereira1,2, J. M. Pereira3,4,5, O. Ribeiro6, J. P. Baptista7, F. Froes8 and J.-A. Paiva3,4,5
1) Polyvalent Intensive Care Unit, Hospital S~ao Francisco Xavier, Centro Hospitalar Lisboa Ocidental , 2) CEDOC, Faculty of Medical Sciences, Universidade Nova
de Lisboa, Lisboa, 3) Emergency and Intensive Care Department, Centro Hospitalar S~ao Jo~ao, 4) Faculty of Medicine, Universidade do Porto, 5) Grupo de Infecc~ao
e Sepsis, 6) Department of Health Information and Decision Sciences, Center for Research in Health Technologies and Information Systems, CINTESIS, Faculty of
Medicine, Universidade do Porto, Porto, 7) Intensive Care Service, Centro Hospitalar e Universitario de Coimbra, Coimbra and 8) Respiratory Intensive Care Unit,
Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
Abstract
A prospective, cohort, clinical, observational study was performed in 14 Intensive Care Units (ICUs) to evaluate the contemporary
epidemiology, morbi-mortality and determinants of outcome of the population with an infection on admission. All 3766 patients admitted
during a consecutive 12-month period were screened. Their median age was 63 [26–83], 61.1% were male and 69.8% had significant
comorbidities. On admission to the ICU 1652 patients (43.9%) had an infection, which was community acquired in 68.2% (one-fifth with
healthcare-associated criteria) and ward-acquired in the others. Roughly half presented to the ICU with septic shock. As much as 488
patients with community-acquired infections were deemed stable enough to be first admitted to the ward, but had similar mortality to
unstable patients directly admitted to the ICU (35.9% vs. 35.1%, p 0.78). Only 48.3% of this infected population had microbiological
documentation and almost one-quarter received inappropriate initial antibiotic therapy. This, along with comorbidities, was a main
determinant of mortality. Overall, infected patients on admission had higher mortality both in the ICU (28.0% vs. 19.9%, p <0.001) and in the
hospital (38.2% vs. 27.5%, p <0.001) and even after being discharged to the ward (14.2% vs. 9.6%, p <0.001). Also, patients not infected on
admission who acquired an infection in the ICU, had an increased risk of dying in the hospital (odds ratio 1.41 [1.12–1.83]). Consequently,
infection, regardless of its place of acquisition, was associated with increased mortality. Improving the process of care, especially first-line
antibiotic appropriateness, and preventing ICU-acquired infections, may lead to better outcomes.
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Introduction
Severe sepsis and septic shock are among the most common
and challenging admission diagnoses in the Intensive Care Unit
(ICU), being associated with high costs, and significant
morbidity and mortality [1]. Several international guidelines,
including the updated Surviving Sepsis Campaign [2], reinforce
the importance of the process of care in the prognosis of
infected patients, especially early appropriate antibiotic ther-
apy, adequate resuscitation and rapid admission to the ICU.
These changes seem to have an impact on the outcome of
severely septic patients and some studies have already shown
improvement [3,4].
Consequently, an updated large study to unveil the present
epidemiology of sepsis and infection on admission to the ICU,
either community or hospital-acquired, is warranted.
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We conducted a 1-year prospective, multicentre,
observational study addressing the epidemiology and the
main determinants of outcome of infection on admission to
ICUs.
Materials and Methods
Study design
The Infection on Admission to the ICU (INFAUCI) study was a
prospective, observational, cohort, multicentre study, con-
ducted in 14 Portuguese ICUs. Data were collected over an
entire 1-year consecutive period, between 1 May 2009 and 31
December 2010. Participation was by direct invitation with no
financial reward.
The Hospital Research and Ethics Committee of Centro
Hospitalar S. Jo~ao approved the design of the study, which has
therefore been performed in accordance with ethical stan-
dards laid down in the 1964 Declaration of Helsinki and its
later amendments. Informed consent was waived due to the
observational nature of the study.
All adult patients (age ≥ 18 years) consecutively admitted
to one of the participating ICUs were enrolled and followed
until death or hospital discharge. Patients were screened for
infection and sepsis at ICU admission. Infected patients were
segregated for further analysis. Only the first ICU admission
during the study period was considered.
Differences between infected and non-infected populations
were addressed along with the process of care and clinical and
microbiological epidemiology of sepsis.
Definitions
Infections and sepsis criteria were identified according to
commonly used definitions [5]. Infection on admission was
divided according to the place of acquisition, either the
hospital or community. Those with community-acquired
sepsis were scrutinized for the presence of healthcare-asso-
ciated infection criteria [6] using a slightly modified definition
(Supporting Information). A new ICU-acquired infection was
defined as an infection that was not present at ICU
admission.
Sepsis severity was classified according to the American
College of Chest Physicians/Society of Critical Care Medicine
Consensus Conference criteria [7]. Severe organ dysfunction
or failure was defined as a Sequential Organ Failure
Assessment (SOFA) score ≥ 3 for each evaluated organ
[8]. In microbiologically documented infections, antibiotic
therapy was considered appropriate if all isolated microor-
ganisms had in vitro sensitivity to at least one of the
prescribed antibiotics.
Data collection and management
Data were prospectively collected at each participating centre
using an especially created database. All data were delivered to
the Department of Biostatistics and Medical Informatics at the
University of Porto, where a dedicated database for the
INFAUCI study was maintained. Patients were given a code
number to secure their anonymity.
An intensive care specialist (JMP) carefully assessed all the
data concerning inconsistencies, which were rechecked with
each centre. Data were screened in detail for missing
information and implausible and outlying values.
Demographic data, admission diagnoses, presence of com-
orbidities and clinical and laboratory data were collected on
the day of ICU admission. The Simplified Acute Physiology
Score (SAPS) II [9] and SOFA score were computed. The days
of ICU and hospital discharge were recorded as well as
occurrence of a new infection in the ICU.
Additional microbiological and clinical data were collected
for all patients who were infected on ICU admission, including
antibiotic therapy.
Statistical analysis
Continuous variables were expressed as median (percentile
(P) 5 – P 95) or mean  standard deviation according to data
distribution. Comparisons between groups were performed
with the unpaired Student’s t-test or Mann–Whitney U-test for
continuous variables and Fisher’s exact test and chi-square test
for categorical variables, as appropriate.
Hospital mortality rate was calculated for the different
sub-groups of infected patients. Multiple logistic regression
analyses were fitted to assess the impact of infection and of
clinically relevant variables on hospital mortality. Odds ratios
(ORs) with 95% confidence interval (CI) were computed. The
Hosmer and Lemeshow test was used to check goodness-of-fit.
Data were analysed using IBM SPSS Statistics v.19.0 (IBM,
Somers, NY, USA). All statistics were two-tailed and the
significance level was defined as p <0.05.
Results
Impact of infection on outcomes
During the study period 3766 patients were admitted to the
participating ICUs. Of those, 1652 (43.9%) were deemed to be
infected on admission. Moreover, as many as 853 patients had
an ICU-acquired infection (n = 379, 22.9% with and n = 474,
22.4% without infection on admission to the ICU). Patients’
characteristics are presented in Table 1. Infected patients
were slightly older, had higher SAPS II and SOFA scores and
longer ICU and hospital length of stay (LOS).
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The presence of infection, either on admission or
ICU-acquired, was associated with increased hospital mortality
(38.2% and 33.1% vs. 26.1%, respectively, p <0.001; Table 2).
Mortality also increasedwith disease severity, assessed in this
study by both SAPS II and SOFA scores and by sepsis severity,
but was lower than predicted by the SAPS II score, both in
infected and non-infected groups (absolute difference of5.6%,
p 0.04 and 1.1%, p 0.57, respectively). The group of infected
patients had longer ICU LOS, (8 [2–38] vs. 4 [2–31], p <0.001).
Infection on admission to the ICU
The population infected on admission to the ICU had higher
mortality, both in the ICU (28% vs. 19.9%, p <0.001) and in the
hospital (38.2% vs. 27.5%, p <0.001), as well as after ICU
discharge (14.2% vs. 9.6%, p <0.001).
Community-acquired infections were identified in 1126
patients, including 20.2% with at least one of the health-
care-associated criteria (Table 3). As many as 488 of them
were deemed stable enough to be first admitted to the ward,
and stayed there for 2 [1–10] days before ICU admission.
Their mortality rate was similar to those with more severe
community-acquired infections who were directly admitted to
the ICU (hospital mortality 35.9% vs. 35.1%, p 0.78).
The main sources of infection are presented in Table 3. The
lung (either pneumonia or tracheobronchitis) was the primary
focus of infection in roughly half of the patients, especially in
TABLE 1. Demographic characteristics of the INFAUCI population
Infection
Total
(n = 3757)
None
(n = 1631; 43%)
ICU-acquired
(n = 474; 13%)
On admission
(n = 1652; 44%) p
Male gender (%) 61 58 69 62 <0.001*
Age (years), median (P05-P95) 63 (29–84) 63 (27–83) 61 (25–83) 64 (31–84) 0.002§
SAPS II, mean (dp) 45  18 41  19 47  15 49  18 <0.001#
SOFA, median 7 (1–15) 5 (1–13) 8 (3–14) 8 (3–17) <0.001§
ICU length of stay 6 (2–34) 3 (1–13) 18 (6–54) 8 (2–38) <0.001§
Hospital length of stay 19 (3–87) 13 (2–84) 35 (8–106) 22 (3–89) <0.001§
Charlson score 4 (0–15) 4 (0–15) 3 (0–13) 5 (0–15) <0.001§
Functional status (%)
Bedridden 2 1 1 2 <0.001*
Independent 89 91 93 86
Limited activity 9 8 5 12
Origin (%)
Surgical ward 33 47 22 24 <0.001*
Medical ward 18 10 9 28
ICU 6 4 9 7
Emergency room 43 39 60 41
ICU mortality 23 19 22 28 <0.001*
Hospital mortality 32 26 33 38 <0.001*
Diagnosis on admission (%)
Postoperative elective 18 35 12 3 <0.001*
Postoperative emergent 18 11 10 27
Heart disease 2 3 3 1
Other medical condition 51 38 38 67
Trauma 11 13 37 3
ICU, Intensive Care Unit.
Patients presented in the ICU-acquired column were not infected on admission.
Significant p values are reported in italic.
*Chi-square test.
#One-way ANOVA.
§Mann–Whitney test.
TABLE 2. Impact of infection on hospital mortality: multivariate analysis
Total
(n = 3765)
Survivors
(n = 2552)
Non-survivors
(n = 1213) OR 95% CI
Age (years), median (P05-P95) 63 (29–84) 61 (27–82) 69 (35–86) <0.01a 1.03 1.02–1.03
Sex (male) 61% 61% 62% <0.4* 1.06 0.92—1.22
Functional status <0.01*
Independent 89% 92% 84% 0.39 0.24–0.63
Dependent 9% 7% 13% 0.78 0.46–1.32
Bedridden 2% 1% 3% 1.0 –
SOFA Day 1 7 [1–15] 6 (1–13) 10 (4–17) <0.01a 1.27 1.24–1.30
Imunosuppression 8% 7% 10% <0.01* 1.43 1.12–1.83
Charlson score 4 (0–15) 4 (0–14) 5 (0–16) <0.01a 1.05 1.04–1.07
Infection <0.01*
None (n = 1631) 43% 47% 35% 1.00 –
On admission (n = 1651) 44% 40% 52% 1.76 1.51–2.04
ICU-acquired only (n = 474) 13% 12% 13% 1.41 1.13–1.75
OR, odds ratio; 95% CI, confidence interval of 95%; P, percentile; SOFA, Sequential Organ Failure Assessment; ICU, Intensive care unit.
Statistically significant odds ratios are displayed in bold.
Significant p values are reported in italic.
*Chi-square test.
aStudent’s t-test.
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community-acquired sepsis (57.1%). Pneumonia was more
common in autumn and winter (57.2% of all pneumonia
episodes, p 0.015), whilst skin and soft tissue infections were
significantly more common during spring and summer (p 0.02).
Septic shock was diagnosed on ICU admission in 51.8% of
the infected patients, especially in those with endovascular
(66.3%) or intra-abdominal infections (65.6%). Hospital mor-
tality increased with sepsis severity, from 20.8% in patients
with sepsis to 30.7% in severe sepsis and 48.8% in patients with
septic shock (p <0.01).
The prevalence of acute organ failure on admission to the
ICU is presented in Fig. 1. Overall, 84.4% of infected patients
had at least one organ failure (median 2 [0–4]). The most
common systems involved were the respiratory (61.3% of
patients) and the cardiovascular (52.7%).
In the multivariate model assessing infected patients
(Table 4), mortality was associated with acute disease severity
itself and host non-modifiable characteristics (age, functional
status and comorbidities). In addition, modifiable process of care
factors also influenced hospital mortality, particularly inappro-
TABLE 3. Risk factors on admission to the intensive care unit for hospital mortality of infected patients: multivariate analysis
Total
(n = 1651)
Survivors
(n = 1020; 62%)
Non-survivors
(n = 631; 38%) AOR 95% CI
Age (years), median (P05‒P95) 64 (31–84) 61 (29–82) 70 (36–86) <0.01a 1.03 1.02–1.04
SAPS II mean  SD 49  18 43  15 58  17 <0.01b 1.04 1.03–1.05
Functional status <0.01*
Independent 86% 90% 79% 1.00 –
Dependent 12% 9% 17% 1.73 1.16–2.56
Bedridden 2% 1% 4% 3.34 1.11–10.04
SOFA Day 1 8 (3–17) 7 (2–14) 10 (4–18) <0.01a 1.07 1.01–1.12
CHF 6% 4% 10% <0.01* 3.469 1.97–6.11
Neurological disease 12% 9% 15% <0.01* 1.66 1.07–2.58
Imunosuppression 11% 8% 14% <0.01* 1.80 1.13–2.87
CRF 10% 7% 14% <0.01* 2.43 1.53–3.86
Sepsis <0.01*
No sepsis/sepsis 19% 24% 10% 1.00 –
Severe sepsis 29% 33% 23% 1.38 0.88–2.15
Septic shock 52% 43% 66% 1.79 1.14–2.81
Nosocomial infection 23% 19% 29% <0.01* 1.81 1.33–2.47
Infection source <0.01*
Pneumonia 45% 44% 47% 1.00 –
Intra-abdominal 27% 26% 27% 0.62 0.44–0.86
Primary bacteraemia 6% 5% 8% 0.73 0.40–1.31
Tracheobronchitis 8% 8% 4% 0.58 0.31–1.09
Skin and soft tissue 5% 5% 6% 1.38 0.75–2.52
Urological 7% 7% 4% 0.20 0.10–0.40
Neurological 4% 4% 1% 0.28 0.07–0.91
Other 2% 2% 2% 0.50 0.20–1.27
Initial antibiotics <0.01*
Appropriate 36% 37% 34% 1.00 –
Inappropriate 12% 9% 17% 2.29 1.49–3.51
Not evaluable 52% 54% 49% 1.20 0.87–1.67
AOR, adjusted odds ratio; 95% CI, confidence interval of 95%; SD, standard deviation; P, percentile; SAPS II, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure
Assessment; CHF, chronic hepatic failure; CRF, chronic renal failure.
Statistically significant adjusted odds ratios are displayed in bold.
Significant p values are reported in italic.
*Chi-square test.
aStudent’s t-test.
bMann–Whitney test.
FIG. 1. Intensive care unit and hospital
mortality according to the number of
failing organs (defined as an organ
Sequential Organ Failure Assessment
(SOFA) score ≥ 3) on admission to
intensive care.
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priate initial antibiotic therapy (OR2.29) and acquisition of a new
ICU-acquired infection (OR 1.81 for the whole population).
Microbiology and antibiotic data
Microbiological documentation was obtained in 48.3% of
infections, including one-quarter with polymicrobial infections,
mostly intra-abdominal. Patients admitted to the ICU with an
infection that was already acquired in the ward also had a low
rate of microbiological documentation, only 50.9%.
In the overall population, Gram-negative bacteria slightly
predominated, constituting 52.3% of microbiological isolates
(Supporting Information). As expected, non-fermentative
Gram-negative bacilli were far more prevalent in patients with
either healthcare-associated or hospital-acquired infections
(almost 30% of Gram-negative bacilli in those settings),
although these bacteria were also occasionally found in
community-acquired infections. Gram-positive bacteria consti-
tuted 36.9% of the isolated pathogens, and fungi 4.0%, mostly
Candida albicans recovered from intra-abdominal infections.
The most prevalent pathogens were Escherichia coli (187
patients) and Staphylococcus aureus (159 patients, 56%methicillin
resistant). Mycobacterium tuberculosis was responsible for sepsis
in 11 patients (10 with pneumonia and one with meningitis).
The initial empirical antibiotic therapy was appropriate in
74.4% of patients (80.4% with community-acquired, 83.8% with
healthcare-associated and 62.8% with hospital-acquired infec-
tions), though broad-spectrum antibiotics were commonly
selected (carbapenems in 13.5%, piperacillin/tazobactam in
17% and an anti-MRSA antibiotic in 11.3%). Moreover,
combination antibiotic therapy was used in 53% of patients.
Time to the start of antibiotic therapy was only measured in
patients with community-acquired infections, being 2 h 30 min
[33 min – 13 h 37 min].
Antibiotic use in the previous 3 months before ICU
admission was very common (41% of the 989 patients for
whom this information was available).
Discussion
The INFAUCI study provides a contemporary analysis of the
epidemiology and outcome of infection among patients
admitted to the ICU. In this large prospective cohort study
almost half of the patients admitted to one of the 14
participating ICUs were infected on the day of admission and
half had septic shock. Also, more than one-fifth of both
patients with and without infection on admission had an
ICU-acquired infection.
This prevalence of infection on admission was much higher
than usually reported in epidemiological studies [10,11] but
TABLE 4. Risk factors on admission to the intensive care unit for hospital mortality of infected patients: multivariate analysis
Total
(n = 1651)
Survivors
(n = 1020; 62%)
Non-survivors
(n = 631; 38%) AOR 95% CI
Age (years), median (P05‒P95) 64 (31–84) 61 (29–82) 70 (36–86) <0.01a 1.03 1.02–1.04
SAPS II mean  SD 49  18 43  15 58  17 <0.01b 1.04 1.03–1.05
Functional status <0.01*
Independent 86% 90% 79% 1.00 –
Dependent 12% 9% 17% 1.73 1.16–2.56
Bedridden 2% 1% 4% 3.34 1.11–10.04
SOFA Day 1 8 (3–17) 7 (2–14) 10 (4–18) <0.01a 1.07 1.01–1.12
CHF 6% 4% 10% <0.01* 3.469 1.97–6.11
Neurological disease 12% 9% 15% <0.01* 1.66 1.07–2.58
Imunosuppression 11% 8% 14% <0.01* 1.80 1.13–2.87
CRF 10% 7% 14% <0.01* 2.43 1.53–3.86
Sepsis <0.01*
No sepsis/sepsis 19% 24% 10% 1.00 –
Severe sepsis 29% 33% 23% 1.38 0.88–2.15
Septic shock 52% 43% 66% 1.79 1.14–2.81
ICU-acquired infection 23% 19% 29% <0.01* 1.81 1.33–2.47
Infection source <0.01*
Pneumonia 45% 44% 47% 1.00 –
Intra-abdominal 27% 26% 27% 0.62 0.44–0.86
Primary bacteraemia 6% 5% 8% 0.73 0.40–1.31
Tracheobronchitis 8% 8% 4% 0.58 0.31–1.09
Skin and soft tissue 5% 5% 6% 1.38 0.75–2.52
Urological 7% 7% 4% 0.20 0.10–0.40
Neurological 4% 4% 1% 0.28 0.07–0.91
Other 2% 2% 2% 0.50 0.20–1.27
Initial antibiotics <0.01*
Appropriate 36% 37% 34% 1.00 –
Inappropriate 12% 9% 17% 2.29 1.49–3.51
Not evaluable 52% 54% 49% 1.20 0.87–1.67
AOR, adjusted odds ratio; 95% CI, confidence interval of 95%; SD, standard deviation; P, percentile; SAPS II, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure
Assessment; CHF, chronic hepatic failure; CRF, chronic renal failure; ICU, Intensive Care Unit.
Statistically significant adjusted odds ratios are displayed in bold.
Significant p values are reported in italic.
*Chi-square test.
aStudent’s t-test.
bMann–Whitney test.
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consistent with previous Portuguese data [12], probably
reflecting the availability of ICU services [13], which remains
relatively low in Portugal. Gram-negative bacteria slightly
predominated, which is in accordance with what was previ-
ously found in Western Europe, although those studies
reported much higher rates of microbiological documentation
[14].
As expected, patients with septic shock had a high mortality
rate, 48.8%, which was remarkably similar to a recent French
epidemiological study (48.7%) [15]. Still, the hospital mortality
of the whole population was lower than predicted by SAPS II
score, and this difference was more evident in the infected
population (absolute difference of 5.6%). Also patients with
organ failure on admission (Fig. 1) had lower mortality than
previously described [16]. This may be related to the
introduction of new potentially effective therapeutic interven-
tions for organ support [17] and to improvements in sepsis
care due to organizational as well as educational efforts,
namely a rapid response system for sepsis, largely implemented
in Portugal [18].
Infection is associated with high treatment costs, mostly
dependent on prolonged LOS [19]. In our study, ICU and
hospital LOS increased in the infected population, indepen-
dently of locality of acquisition (either community, ward or
ICU), which is quite similar to other European studies [20].
Improvements in the process of care are associated with
the decrease in mortality and costs [2]. Early and appropriate
antibiotic therapy [21] and adequate fluid resuscitation [2] are
well known strategies to improve the outcome. We unveiled
other potential areas that may influence the outcome of
severely infected patients, namely assuring timely ICU admis-
sion and appropriate initial antibiotic therapy, maximizing
microbiological documentation, preventing new ICU-acquired
infections and carefully selecting the discharge area for
post-ICU care.
In our study only 56.7% of patients with commu-
nity-acquired sepsis were directly admitted to the ICU.
Commonly, septic patients treated in the ward have low
mortality rates [22,23] whilst, in our cohort, patients who
were deemed stable enough to be first admitted to the ward,
but later deteriorated and needed ICU admission, had similar
ICU and hospital mortality rates as the more severely septic
population, directly admitted to the ICU. Timely admission of
those patients to the ICU may help to preserve their organ
functions and improve the outcomes.
In addition, in 20.2% of our population with a commu-
nity-acquired infection, at least one of the healthcare-associ-
ated infection criteria was present. Although the prevalence of
multiresistant bacteria in these infections is controversial
[6,24], we found a higher prevalence of both Pseudomonas
aeruginosa and MRSA in this group of patients. This high
prevalence of multiresistant microrganisms, along with the
common findings of polymicrobial infections and previous use
of antibiotic therapy, all impacted on the low rate of empirical
antibiotic adequacy (only 74.4%), despite the common use of
both broad-spectrum and combination antibiotic therapy.
Although the relationship between inappropriate initial antibi-
otic therapy and mortality may not be so straightforward [25],
we believe that prompt adequate antimicrobial treatment is a
cornerstone of severe sepsis management [21,26]. Conse-
quently, a reduction of the overuse of antibiotics and the
promotion of microbiological surveillance studies are advis-
able.
Less than half of our infected population had microbiological
documentation. Even in the 31.2% of patients who had already
acquired their infection in the ward, a disappointingly low rate
of microbiological identification, only 50.9%, was noted. A
cooperative approach between the ICU, emergency room and
ward physicians may improve the collection of microbiological
samples before starting antibiotic therapy, critical for the use
of an antibiotic stewardship programme.
Previous studies had documented an occult mortality in the
ward, after ICU discharge, especially of the septic population
[27], which was similar to our findings. The careful assessment
of patients’ risk at the time of ICU discharge and the
promotion of adequate sequential hospital care, namely a
more prolonged ICU stay or an intense surveillance in a
high-dependency unit [28], may benefit these patients. A
potential role for C-reactive protein in identifying this high-risk
population has been proposed [29,30].
Finally, ICU-acquired infections were equally common both
in patients with and without infection on admission and this
had an impact on mortality and LOS. An effective prevention
strategy to minimize healthcare-associated infections may
improve patients’ outcomes.
All these five different process of care areas are potentially
modifiable risk factors for mortality and should be properly
addressed in future studies.
Our study has some limitations. We only included ICUs
from Portugal and therefore selection bias may have occurred.
However, we think that the contributing multipurpose ICUs
are fairly representative of European ICUs. We also recognize
that the limited number of ICU beds in Portugal may have led
to a selection of the population with the highest severity and,
consequently, some critically ill patients may have been treated
in high-dependency units or even in the ward. Furthermore, as
this was an observational study, we did not validate the local
criteria used for infection diagnosis and both over- and
under-diagnosis, as well as inconsistencies, may have occurred.
We attempted to minimize errors by using standardized
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definitions and reviewing all data to check for inconsistencies,
missing information and implausible and outlying values, which
were sent back to each centre for confirmation.
We think that our pragmatic approach, selecting patients
according to the diagnostic evaluation made by the local
physician in charge, including infections of both community and
hospital origin during one whole year, and the fact that we
were able to constitute a large cohort of infected patients,
strengthen the external validity of our results.
Conclusion
In the INFAUCI study, patients admitted to the ICU had a very
high rate of infection and septic shock. Mortality was associated
with acute disease, host characteristics and the presence of
infection, either existent on admission or acquired in the ICU.
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